<https://helda.helsinki.fi>

Probiotics and Upper Respiratory Tract - a Review

Tapiovaara, Laura

2016-07

Tapiovaara , L , Pitkäranta , A I & Korpela , R 2016 , ' Probiotics and Upper Respiratory Tract - a Review ' , Pediatric Infectious Disease Journal , vol. 1 , no. 3 , 19 . <https://doi.org/10.4172/PIDO.100019>

<http://hdl.handle.net/10138/175832>
<https://doi.org/10.4172/PIDO.100019>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Probiotics and the Upper Respiratory Tract - A Review

Laura Tapiovaara^{1*}, Anne Pitkaranta¹ and Riitta Korpela²

¹Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland

²Faculty of Medicine, Pharmacology, Medical Nutrition Physiology, University of Helsinki, Helsinki, Finland

*Corresponding author: Laura Tapiovaara, Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Email: laura.k.tapiovaara@helsinki.fi

Received date: June 24, 2016; Accepted date: July 12, 2016; Published date: July 18, 2016

Citation: Tapiovaara L, Pitkaranta A, Korpela R (2016) Probiotics and the Upper Respiratory Tract - A Review. *Pediatric Infect Dis* 1:19. doi: 10.4172/PIDO.100019

Copyright: © 2016 Tapiovaara L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

The interest in gut micro biota has emerged in recent decades. Gut micro biota has been associated with the promotion of health, the increased risk of disease, and the maintenance of some diseases. Upper respiratory infections caused by viruses are among the most common health problems in humans [1]. In addition to the misery of sickness, these infections result in a significant burden on society in terms of healthcare visits, absences from work, and reduced school attendance. In addition, unnecessary medical costs are incurred. The careless use of antibiotics during respiratory tract infections has resulted in the constantly growing resistance of microbes to antibiotics [2]. The complications of upper respiratory infections, such as otitis and sinusitis, also result in high expenses and expose patients to potentially harmful operations. If viral upper respiratory infections could be prevented and treated, these outlays would be minimized.

According to a panel of international experts, "probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host" [3,4]. The strain should be precisely defined (i.e., identified and characterized), the dose should be defined, the health claim should be indicated, and the safety should be assessed. The properties of probiotics vary widely according to the strain. Even the manufacturing process influences the properties of certain strains [5].

Lactobacillus rhamnosus GG (L. GG, ATCC 53103) is one of the most-often studied probiotics. This bacterial strain of human origin has been isolated from the human gut. Its benefits in GI disorders have been demonstrated [6], and similar effects have been found in upper respiratory infections [7,8]. Although the colonization of the gut and the fecal recovery of specific probiotics, including L. GG, have been extensively studied, little information is available on the colonization of the upper respiratory epithelium where the lymphatic system is present. Even less is known about the effects of the possible colonization of the related mucosal tissues.

Probiotics are widely added to commercial dairy products and food products, and they are increasingly consumed as supplements [9]. The safety of L. GG has been monitored since 1989. A few case reports have described infections caused by probiotics, such as bacteremia, endocarditis, and internal organ abscesses. However, the incidence of *Lactobacillus bacteremia* has remained stable although the consumption of probiotic products has increased exponentially [10]. Infections seem to be very sparse and affect mostly immunocompromised or critically ill patients [11]. Probiotic consumption has been documented as safe in neonates and even in preterm infants [12]. A report from Finland suggested that L. GG is safe for premature infants based on 12 years of its administration to all premature and very low birth weight infants born in the area around one university hospital [13].

Probiotics and their health effects

Probiotics should fulfil the following criteria: they must survive in the gastrointestinal tract and be able to proliferate in the gut; they should benefit the host through growth and/or activity in humans; and they should be non-pathogenic and non-toxic [14]. Probiotic micro-organisms exist in multiple genus, species, and strains. Although recent evidence suggests that they have some common health effects, they have many strain-specific health effects [4]. The most common probiotic organisms are bacteria from the genus *Bifidobacterium* and the genus *Lactobacilli* [15]. The findings of broad meta-analyses of strain-specific probiotics support that common health benefits are derived from consuming an adequate dose of any safe strain of a species that is already known to be an effective probiotic. For example, a meta-analysis of different strains and 10,351 patients found that probiotics had a positive effect on eight gastrointestinal diseases across the all studied probiotic species [16]. However, the results showed differences in efficacy regarding specific diseases and specific differences in strains.

Professional medical organizations have made clinical recommendations of well-defined specific probiotics for specific clinical conditions. In particular, gastrointestinal conditions have shown health effects: probiotics are

recommended in the treatment and prevention of acute gastroenteritis, necrotizing enterocolitis, and antibiotic-associated diarrhea [17]. They can be supplemented with infant formula to enhance growth and improve clinical outcomes although evidence is still lacking [18]. Some evidence exists to support the use of probiotics in several conditions: constipation, irritable bowel syndrome, inflammatory bowel diseases, lactose intolerance, allergies, atopic eczema, certain cancers, hepatic diseases, hyperlipidaemia, *Helicobacter pylori* infection, genitourinary tract infections, and oral health [19,20]. In 2015, the World Allergy Organization (WAO) convened a guideline panel to develop evidence-based recommendations for the use of probiotics in the prevention of allergy [21]. The European Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) association has also established recommendations for the use of probiotics in the prevention and treatment of acute gastroenteritis in children [22]. ESPGHAN recommends the use of specific, well-studied probiotics to prevent and treat acute gastroenteritis in infants and children and to reduce the side-effects associated with antibiotics [22]. In addition, the meta-analysis of a specific probiotic strain concluded that L. GG was effective in preventing antibiotic-associated diarrhea in children and adults who were treated with antibiotics for any reason [23].

Mechanisms of action

The mechanisms of the action of probiotics in viral and bacterial infections are not completely understood. Specific probiotics show strain-specific potential for reinforcing the integrity of the intestinal epithelium and regulating immune components. In regulating complex immune responses, the gastrointestinal tract from the oral cavity to the rectum is considered the largest immune interface with the environment [24]. The potential mechanisms are studied mainly in the gastrointestinal epithelium. Some postulated mechanisms of probiotic action in intestinal epithelial defense are presented in Figure 1, Adapted from Wan et al. [25]. The potential mechanisms of action in the upper respiratory tract remain unknown, and similar mechanisms than in intestinal epithelium may exist, but the topic needs to be studied further.

It is possible that probiotic bacteria could bind to an invading virus, thus inhibiting virus attachment to the host-cell receptor [26]. Lactic acid bacteria may exert antiviral activity by the following: 1) direct interaction as an adsorptive or trapping mechanism; 2) stimulation of the immune system by interleukin, natural killer cells, Th1 immune response activity, and IgA production; 3) production of antiviral agents (e.g., hydrogen peroxide, lactic acid, and bacteriocins) [27].

Figure 1: Possible mechanisms by which probiotic bacteria modulate intestinal defence responses

Acute viral respiratory infections

Acute viral upper respiratory infections (URI), which are also known as the common cold, are among the most common health problems in humans [28]. The economic burden on society of the otherwise usually benign disease is enormous because of absences from work, school, and daycare, as well as the utilization of health care providers and treatments. In the USA, 25 million health care visits a year are made because of URI [29]. On average, children 1-2 years of age experience 3-8 respiratory infections yearly, and children over 5 years of age experience about three respiratory infections yearly [30,31].

More than 200 viruses are known to cause respiratory infections in humans [32]. Major pathogens that induce URIs are human rhinoviruses (HRVs) from the family *Picornaviridae*, genus *Enterovirus* [33]. Other common causative agents are respiratory syncytial virus (RSV), parainfluenza virus, enterovirus (EV), coronavirus, influenza virus, and adenovirus [34]. Of these, influenza virus, RSV, and parainfluenza virus are more frequent causes of lower than upper respiratory infections [28,31,35]. The symptoms of URI arise after an incubation period that varies depending on the causative agent.

Colonization of upper respiratory tract with probiotics

Colonization of the gut epithelium by probiotics has been extensively studied [36-38]. Mucosal adhesion is incorrectly taught as essential for both non-immune and mucosal immune defense mechanisms. For example, noncolonizing probiotics, such as *Lactobacillus casei*, may exert their functions in a transient manner or by influencing the existing microbial community [39]. Thus far, few trials have investigated the colonization of upper respiratory tract with probiotics. In a pilot study, probiotic *Lactobacillus plantarum* DSM9843 was

cultured from the tonsillar surfaces of 6 subjects up to eight hours after the per oral consumption of fermented oatmeal gruel enriched with this probiotic [40]. Another small population trial investigated the recovery of *Streptococcus salivarius* K12 in the nasopharynx and oral cavity after oral intake [41]. In this study, one of 19 nasopharyngeal cultures was reported positive for the probiotic, and it was recovered from three adenoids of the seven examined. Tonsillar recovery of L. GG after per oral consumption was studied in 57 young adults in a placebo-controlled and randomized trial [42]. L. GG was recovered in 40% of the L. GG groups' tonsillar samples and in 30% of the placebo groups' samples. In a recent trial, 20 adults were treated with intranasal *Streptococcus salivarius* 24SMBc for three days [43]. The results showed that 95% of

the subjects were colonized in the nasopharynx with the probiotic at least four hours after spray administration; colonization persisted for at least six days in 55% of the subjects. L. GG was also recovered from adenoid tissue of children consuming probiotic per orally in a randomized double-blinded study [44]. Here, all subjects who consumed L. GG presented with the bacteria in the adenoid, as well as 76% of the placebo groups samples were positive. Twenty-five middle ear effusion samples of the same study population were studied in another trial [45]. In this study, 21% in the L. GG group presented with L. GG and 7% in the placebo group presented with L. GG in the middle ear. These studies are presented in Table 1.

Table 1: Characteristics of the previous studies investigating the colonization of upper respiratory tract with probiotics; RDBPC=randomized, placebo-controlled, prospective clinical trial

Subjects	Design and duration	Probiotic supplementation	Main findings	Reference
Healthy volunteers, mean age 38 (n=6)	Swab samples from tonsils after single per oral intake	<i>L. plantarum</i> (2×10^{11} cfu)	Colonization remained for 8 h	Stjernquist-Desatnik et al. [40]
Children scheduled for tympanostomy, aged 0.5-5 years (n=19)	Swab samples from tongue and nasopharynx, 10 days	<i>S. salivarius</i> K12 (1.7×10^{10} cfu)	33% colonized	Power et al. [41]
Young adults scheduled for tonsillectomy, mean age 24.5 years (n=57)	RDBPC Tonsil tissue samples, 3 weeks	L. GG (2×10^{10} cfu) or multispecies L. GG, Lc705, PJS, BB12	30-40% colonized NS in different intervention groups	Kumpu et al. [42]
Healthy adults aged 30-54 (n=20)	Nasal spray, rhinopharyngeal swabs, 3 days	<i>S. salivarius</i> 24SMBc (8×10^9 cfu)	95% colonized 55% remained for six days	Santagati et al. [43]
Children scheduled for adenotomy, median age 37,8 mo (n=31)	RDBPC Adenoid samples, 3 weeks	L. GG ($8-9 \times 10^9$ cfu) $\times 2$	100% colonized in L. GG group, 76% in placebo group	Swanlung et al. [44]
Children scheduled for tympanostomy, median age 31 mo (n=13)	RDBPC MEE samples, 3 weeks	L. GG ($8-9 \times 10^9$ cfu) $\times 2$	21% colonized in L.GG group, 7% in placebo group	Tapiovaara et al. [45]

Clinical effects of probiotics in the upper respiratory tract

The prevention of upper respiratory infections by the use of probiotics has been studied in several trials. For instance, L. GG alone or in combination with other probiotics was shown to reduce the incidence or risk of URI in children [46-48]. A recent systematic review found a favourable outcome of the use of probiotics in reducing the episodes of new respiratory infection in children [49]. However, further studies are required to confirm these results. A recent Cochrane database review of the use of probiotics in URI found 13 randomized controlled trials with participants in several age groups [50] (Table 2). Probiotics were found to be better than the placebo in reducing the number of subjects who experienced acute URI, the mean duration of acute URI, the number of antibiotic prescriptions, and cold-related school absences. However, the quality of evidence was considered low or very low.

A meta-analysis of randomized, placebo-controlled trials indicates that L. GG is able to reduce the incidence of acute otitis media (AOM) and antibiotic prescriptions and decrease the risk of URI in children [51]. However, in otitis-prone children with nasopharyngeal pathogen colonization, L. GG did not reduce the occurrence of AOM [52]. A novel treatment model of intranasal spray bacteriotherapy with *Streptococcus sanguinis* was found to be effective in decreasing MEE in children with prolonged otitis media with effusion (OME) [53]. Statistically significant recovery was achieved with *Streptococcus sanguinis*, and a more modest, yet positive effect was achieved with L. GG. In otitis-prone children, the consumption of L. GG, Lc705, BB99, and PJS significantly reduced the number of positive human bocavirus nasopharyngeal samples [54]. The colonization of the epithelium of the upper respiratory system with specific probiotics or lactic acid bacteria is not well known. *Lactobacillus plantarum* DSM 9843 was recovered from the tonsillar surface after oral administration, suggesting that the strain may possess the capacity to adhere to tonsillar cells [40].

Streptococcus salivarius K12 was cultured from the nasopharynx of infants after the consumption of an oral powder prepared with this probiotic bacterium [41]. Furthermore, L. GG was recovered from tonsil tissue after oral consumption, and prolonged adhesion (over 4 weeks) was suspected [42]. The consequences of colonization are

unknown. An *in vitro* experiment indicates that L. GG is able to inhibit the adherence of *Streptococcus pneumoniae* to human epithelial cells [55]. Two review studies suggested that specific probiotics interact with pathogens and have the potential to reduce pathogen colonization in the nasopharynx, thus potentially reducing AOM and URI [26,56].

Table 2: Characteristics of the included randomized controlled studies in Hao et al. 2015; RD=randomized, B=placebo-controlled, P=prospective, C=clinical trial

Subjects	Design and duration	Probiotic supplementation	Main findings: Probiotic vs. placebo	Reference
Healthy adults aged 18-65 (n=318)	RDBPC, 3 month	<i>L. plantarum</i> and <i>L. paracasei</i> (1×10^9 cfu)	Incidence of common cold episodes ↓ Number of days with respiratory symptoms ↓	Berggren et al. [75]
Day-care children aged 1-5 (n=398)	RDBC, 3 month	<i>L. rhamnosus</i> HN001 (10^{10} cfu)	Number and duration of URI ↔ Level of secretory IgA ↑	Cáceres et al. [76]
Older volunteers in daycare facilities (n=154)	RDBPC, 5 month	<i>L. casei</i> strain <i>Shirota</i> (4×10^{10} cfu)	Number of acute URI and symptom score ↔	Fujita et al. [77]
Day-care children aged 13-86 month (n=281)	RDBPC, 3 month	<i>L. rhamnosus</i> GG (10^9 cfu)	Risk of URI ↓ Days with respiratory symptoms ↓	Hojsak et al. [7]
Hospitalized in pediatric department, over 1-year-old (n=742)	RDBPC, duration of hospitalization	<i>L. rhamnosus</i> GG (10^9 cfu)	Risk of URI ↓ Episodes of URI >3 days ↓	Hojsak et al. [8]
Healthy volunteers aged 69-80 (n=60)	RPC, 2 or 3 month	<i>L. bulgaricus</i> ($1.8-3.2 \times 10^{10}$ cfu) and <i>S. thermophilus</i> ($5.7-7.9 \times 10^{10}$ cfu)	Risk of URI ↓ Natural killer cell activity ↑	Makino et al. [78]
Healthy day-care or school children aged 3-6 (n=638)	RDBPC, 3 month	<i>L. casei</i> (2×10^{10} cfu), <i>S. thermophilus</i> and <i>L. bulgaricus</i> (10^9 cfu)	Incidence for common infectious diseases ↓	Merenstein et al. [79]
Infants needing formula aged 0-2 month (n=81)	RDBPC, 12 month	<i>L. rhamnosus</i> and <i>B. lactis</i> BB-12 (1×10^{10} cfu)	Risk of URI ↓ Risk of AOM and antibiotics ↓	Rautava et al. [47]
Healthy children aged 8-13 (n=80)	RDBPC, 3 month	<i>L. acidophilus</i> and <i>B. bifidum</i> (1×10^9 cfu)	Symptoms of URI ↓ Absences from school related to URI ↓	Rerksupphaphol et al. [80]
Children aged 6-25 mo (n=100)	RPC, 3 month	<i>L. acidophilus</i> and <i>L. casei</i> (10^9 - 10^{10} cfu)	Episodes of respiratory tract infections ↓	Rio et al. [81]
School children aged 3-12 years (n=251)	RDBPC, 5 month	<i>L. casei</i>	Duration of lower respiratory infections ↓	Cobo Sanz et al. [82]
College students aged 18-24 (n=198)	RDBPC, 3 month	<i>L. rhamnosus</i> GG and <i>B. animalis</i> ssp. <i>lactis</i> BB-12	Duration of URI ↓ Median severity score ↓ Missed school days ↓	Smith et al. [83]
Healthy adults, average age 38 ± 13 (n=479)	RDBPC, 8.5 month	<i>L. gasseri</i> , <i>B. longum</i> , and <i>B. bifidum</i> (5×10^7 cfu)	Duration of URI ↓ Total symptom score ↓ Days with fever during URI ↓	de Vrese et al. [84]

Discussion

The nasopharyngeal and adenoid micro biota is a complex interactive system, and the consequences of changing the

proportions, such as by probiotic colonization, remain unknown. The nasopharynx harbors a wide variety of bacteria and viruses, both commensal and pathogenic [57,58]. The bacterial composition of nasopharyngeal micro biota differs

from other body parts, which was surveyed in healthy Chinese young adults [59]. The nasopharyngeal micro biota presented with potentially invasive bacteria, such as *Streptococcus pneumoniae*, *H. influenzae*, *Staphylococcus aureus*, *M. catarrhalis*, and *Neisseria meningitidis* in an overall healthy population [60,61]. In children, the nasopharyngeal micro biota was noted to change according to the season [60]. Furthermore, certain commensal taxa were found to be negatively associated with AOM pathogens, and the proportions of taxa changed depending on the use of antibiotics [62]. Respiratory viruses have been shown to accomplish changes in bacterial adhesion [63], colonization [64] and immunological mechanisms [65] in the nasopharynx. Eventually, complex interactions between viruses and bacteria in the nasopharyngeal epithelium can evoke bacterial superinfections [66].

It has been suggested that nasopharyngeal micro biota could affect subjects' vulnerability to respiratory infections. In an experimental HRV challenge trial, significant differences in two nasopharyngeal genera (*Neisseria* and *Propionibacterium*) were identified between HRV-infected and non-infected subjects [67]. Furthermore, a previous study showed that young children presented with a small number of bacterial taxa in high total numbers in their nasopharynx, contrary to their parents who presented with much more diverse taxa with lower bacterial carriage [68]. This finding suggests that a greater variety of nasopharyngeal micro biota could protect the subject against URI. It is possible that the maturation of the host-associated microbial community happens similarly in the nasopharyngeal area and in the gut [69]. Interestingly, the development of nasopharyngeal micro biota was studied in 60 healthy infants, and certain micro biota patterns were found to be associated with decreases in URI episodes reported by the parents [70]. Furthermore, nasopharyngeal micro biota, especially *Streptococcus*, has been implicated to children's risk of developing asthma [71]. These aspects of microbial diversity in the nasopharynx are also considered when breastfeeding is recommended [70,72].

Microbes can adhere directly to each other, but effects can also occur through adhesion on the host's mucosal surfaces. Highly evolved relationships between the upper respiratory micro biota exist, and it is important to understand those interactions, especially when the micro biota is manipulated. In probiotic settings, knowledge of the colonization of the respiratory epithelium is valuable for further research to investigate the effects of probiotics on the natural micro biota.

Over the past decades, gut micro biota has been increasingly recognized as one of the main factors in the increasing prevalence of immunity-related disorders, such as inflammation, atopy, asthma, musculoskeletal disorders, liver fibrosis, diabetes mellitus type 2, metabolic syndrome, cardiovascular diseases, neurodegenerative diseases, atherosclerosis, and cancer, which is also known as the hygiene hypothesis [73]. The research on metagenomics has contributed information on how the micro biota interacts with the host's physiology and has started to provide new therapeutically targets. Finally, by better understanding the

role of gut micro biota, the individual's micro biota could be integrated into personalized healthcare, and the individual's diseases could be targeted and treated more efficiently. However, the complete understanding of the disease process is required to determine whether targeting gut micro biota would be effective or not [74].

Funding

The study is funded by the Sal We research program GET IT DONE (Tekes, the Finnish Funding Agency for Technology and Innovation, grant number 3986/31/2013).

Competing Interests

All authors declare any competing interests.

References

1. Fendrick AM, Monto AS, Nightengale B, Sarnes M (2003) The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Arch Intern Med* 163: 487-494.
2. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, et al. (2015) The global threat of antimicrobial resistance: science for intervention. *New Microbes New Infect* 6: 22-29.
3. WHO/FAO (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria, Córdoba, Argentina, pp: 1-4.
4. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, et al. (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 11: 506-514.
5. GrzeÅkowiak Å, Isolauri E, Salminen S, Gueimonde M (2011) Manufacturing process influences properties of probiotic bacteria. *Br J Nutr* 105: 887-894.
6. Vitetta L, Briskey D, Alford H, Hall S, Coulson S (2014) Probiotics, prebiotics and the gastrointestinal tract in health and disease. *Inflammopharmacology* 22: 135-154.
7. Hojsak I, AbdoviÄš S, Szajewska H, MiloseviÄš M, KrznariÄš Z, et al. (2010) Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. *Pediatrics* 125: e1171-1177.
8. Hojsak I, Snovak N, AbdoviÄš S, Szajewska H, Misak Z, et al. (2010) Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. *Clin Nutr* 29: 312-316.
9. Siró I, Kápolna E, Kápolna B, Lugasi A (2008) Functional food. Product development, marketing and consumer acceptance-a review. *Appetite* 51: 456-467.
10. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, et al. (2002) Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. *Clin Infect Dis* 35: 1155-1160.

11. Boyle RJ, Robins-Browne RM, Tang ML (2006) Probiotic use in clinical practice: what are the risks? *Am J Clin Nutr* 83: 1256-1264.
12. AlFaleh K, Anabrees J (2013) Efficacy and safety of probiotics in preterm infants. See comment in PubMed Commons below *J Neonatal Perinatal Med* 6: 1-9.
13. Luoto R, Isolauri E, Lehtonen L (2010) Safety of Lactobacillus GG probiotic in infants with very low birth weight: twelve years of experience. *Clin Infect Dis* 50: 1327-1328.
14. Wassenaar TM, Klein G (2008) Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. *J Food Prot* 71: 1734-1741.
15. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A (2012) World Gastroenterology Organization World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. *J.Clin.Gastroenterol* 46: 468-481.
16. Ritchie ML, Romanuk TN (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS One* 7: e34938.
17. Ebner S, Smug LN, Kneifel W, Salminen SJ, Sanders ME (2014) Probiotics in dietary guidelines and clinical recommendations outside the European Union. *World J Gastroenterol* 20: 16095-16100.
18. Braegger C, Chmielewska A, Decsi T, Kolacek S, Mihatsch W, et al. (2011) Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr* 52: 238-250.
19. Brown AC, Valiere A (2004) Probiotics and medical nutrition therapy. *Nutr Clin Care* 7: 56-68.
20. Kopp-Hoolihan L (2001) Prophylactic and therapeutic uses of probiotics: a review. *J Am Diet Assoc* 101: 229-238.
21. Fiocchi A, Pawankar R, Cuello-Garcia C, Ahn K, Al-Hammadi S, et al. (2015). World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. *World Allergy Organ J* 8: 4.
22. Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, et al. (2014) European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. *J PediatrGastroenterol Nutr* 58: 531-539.
23. Szajewska H, Kolodziej M (2015) Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. *Aliment Pharmacol Ther* 42: 1149-1157.
24. MacDonald TT, Monteleone I, Fantini MC, Monteleone G (2011) Regulation of homeostasis and inflammation in the intestine. *Gastroenterology* 140: 1768-1775.
25. Wan LY, Chen ZJ, Shah NP, El-Nezami H (2015) Modulation of Intestinal Epithelial Defense Responses by Probiotic Bacteria. *Crit Rev Food Sci Nutr*.
26. Salminen S, Nybom S, Meriluoto J, Collado MC, Vesterlund S, et al. (2010) Interaction of probiotics and pathogens--benefits to human health? *Curr Opin Biotechnol* 21: 157-167.
27. Al Kassaa I, Hober D, Hamze M, Chihib NE, Drider D (2014) Antiviral potential of lactic acid bacteria and their bacteriocins. *Probiotics Antimicrob Proteins* 6: 177-185.
28. Heikkinen T, Järvinen A (2003) The common cold. *Lancet* 361: 51-59.
29. Gonzales R, Malone DC, Maselli JH, Sande MA (2001) Excessive antibiotic use for acute respiratory infections in the United States. *Clin Infect Dis* 33: 757-762.
30. Wald ER, Guerra N, Byers C (1991) Upper respiratory tract infections in young children: duration of and frequency of complications. *Pediatrics* 87: 129-133.
31. Nokso-Koivisto J, Hovi T, PitkÄ ranta A (2006) Viral upper respiratory tract infections in young children with emphasis on acute otitis media. *Int J Pediatr Otorhinolaryngol* 70: 1333-1342.
32. Eccles R (2005) Understanding the symptoms of the common cold and influenza. *Lancet Infect Dis* 5: 718-725.
33. Fendrick AM (2003) Viral respiratory infections due to rhinoviruses: current knowledge, new developments. *Am J Ther* 10: 193-202.
34. Passiotti M, Maggina P, Megremis S, Papadopoulos NG (2014) The common cold: potential for future prevention or cure. *Curr.Allergy Asthma Rep* 14: 413.
35. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, et al. (1998) Viruses and bacteria in the etiology of the common cold. *J Clin Microbiol* 36: 539-542.
36. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. *Appl Environ.Microbiol* 65: 351-354.
37. Ramakrishna BS (2009) Probiotic-induced changes in the intestinal epithelium: implications in gastrointestinal disease. *Gastroenterol* 30: 76-85.
38. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A (2012) Probiotic mechanisms of action. *Ann Nutr Metab* 61: 160-174.
39. Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. *Am J Physiol Gastrointest Liver Physiol* 298: 807-819.
40. Stjernquist-Desatnik A, Warfving H, Johansson ML (2000) Persistence of Lactobacillus plantarum DSM 9843 on human tonsillar surface after oral administration in fermented oatmeal gruel. A pilot study. *Acta Otolaryngol* 543: 215-219.
41. Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg JR (2008) Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. *Eur J Clin Microbiol Infect Dis* 27: 1261-1263.
42. Kumpu M, Swanljung E, Tynkkynen S, Hatakka K, Kekkonen RA, et al. (2013) Recovery of probiotic Lactobacillus rhamnosus GG in tonsil tissue after oral administration: randomised, placebo-controlled, double-blind clinical trial. *Br J Nutr* 109: 2240-2246.
43. Santagati M, Scillato M, Muscaridola N, Metoldo V, La Mantia I, et al. (2015) Colonization, safety, and tolerability study of the Streptococcus salivarius 24SMBc nasal spray for its application in upper respiratory tract infections. *Eur J Clin Microbiol Infect Dis* 34: 2075-2080
44. Swanljung E, Tapiovaara L, Lehtoranta L, Makivuokko H, Roivainen M, et al. (2015) Lactobacillus rhamnosus GG in adenoid tissue: Double-blind, placebo-controlled, randomized clinical trial. *Acta Otolaryngol* 135: 824-830.
45. Tapiovaara L, Lehtoranta L, Swanljung E, Makivuokko H, Laakso S, et al. (2014) Lactobacillus rhamnosus GG in the middle ear after

- randomized, double-blind, placebo-controlled oral administration. *Int J Pediatr Otorhinolaryngol* 78: 1637-1641.
46. Hatakka K, Savilahti E, Pönkä A, Meurman JH, Poussa T, et al. (2001) Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. *BMJ* 322: 1327.
 47. Rautava S, Salminen S, Isolauri E (2009) Specific probiotics in reducing the risk of acute infections in infancy--a randomised, double-blind, placebo-controlled study. *Br J Nutr* 101: 1722-1726.
 48. Kumpu M, Kekkonen RA, Kautiainen H, Jarvenpää S, Kristo A, et al. (2012) Milk containing probiotic *Lactobacillus rhamnosus* GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. *Eur J Clin Nutr* 66: 1020-1023.
 49. Araujo GV, de Oliveira Junior MH, Peixoto DM, Sarinho ES (2015) Probiotics for the treatment of upper and lower respiratory-tract infections in children: systematic review based on randomized clinical trials. *J Pediatr (Rio J)* 91: 413-427.
 50. Hao Q, Dong BR, Wu T (2015) Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database Syst Rev* 2: CD006895.
 51. Liu S, Hu P, Du X, Zhou T, Pei X. (2013) *Lactobacillus rhamnosus* GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. *Indian Pediatr* 50: 377-381.
 52. Hatakka K, Blomgren K, Pohjavuori S, Kaijalainen T, Poussa T, et al. (2007) Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. *Clin Nutr* 26: 314-321.
 53. Skovbjerg S, Roos K, Holm SE, Grahn Håkansson E, Nowrouzian F, et al. (2009) Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. *Arch Dis Child* 94: 92-98.
 54. Lehtoranta L, Söderlund-Venermo M, Nokso-Koivisto J, Toivola H, Blomgren K, et al. (2012) Human bocavirus in the nasopharynx of otitis-prone children. *Int J Pediatr Otorhinolaryngol* 76: 206-211.
 55. Wong SS, Quan Toh Z, Dunne EM, Mulholland EK, Tang ML, et al. (2013) Inhibition of *Streptococcus pneumoniae* adherence to human epithelial cells in vitro by the probiotic *Lactobacillus rhamnosus* GG. *BMC Res Notes* 6: 135.
 56. John M, Dunne EM, Licciardi PV, Satzke C, Wijburg O, et al. (2013) Otitis media among high-risk populations: can probiotics inhibit *Streptococcus pneumoniae* colonisation and the risk of disease? *Eur J Clin Microbiol Infect Dis* 32: 1101-1110.
 57. Chi DH, Hendley JO, French P, Arango P, et al. (2003) Nasopharyngeal reservoir of bacterial otitis media and sinusitis pathogens in adults during wellness and viral respiratory illness. *Am J Rhinol* 17: 209-214.
 58. Skevaki CL, Tsiaila P, Trochoutsou AI, Logotheti I, Makrinioti H, et al. (2015) Associations Between Viral and Bacterial Potential Pathogens in the Nasopharynx of Children With and Without Respiratory Symptoms. *Pediatr Infect Dis J* 34: 1296-1301.
 59. Ling Z, Liu X, Luo Y, Yuan L, Nelson KE, et al. (2013) Pyrosequencing analysis of the human micro biota of healthy Chinese undergraduates. *BMC Genomics* 14: 390.
 60. Bogaert D, Keijsers B, Huse S, Rossen J, Veenhoven R, et al. (2011) Variability and diversity of nasopharyngeal micro biota in children: a metagenomic analysis. *PLoS One* 6: e17035.
 61. Hendley JO, Hayden FG, Winther B (2005) Weekly point prevalence of *Streptococcus pneumoniae*, *Hemophilus influenzae* and *Moraxella catarrhalis* in the upper airways of normal young children: effect of respiratory illness and season. *APMIS* 113: 213-220.
 62. Pettigrew MM, Gent JF, Pyles RB, Miller AL, Nokso-Koivisto J, et al. (2011) Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. *J Clin Microbiol* 49: 3750-3755.
 63. Avadhanula V, Rodriguez CA, Devincenzo JP, Wang Y, Webby RJ, et al. (2006) Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. *J Virol* 80: 1629-1636.
 64. Tong HH, Weiser JN, James MA, DeMaria TF (2001) Effect of influenza A virus infection on nasopharyngeal colonization and otitis media induced by transparent or opaque phenotype variants of *Streptococcus pneumoniae* in the chinchilla model. *Infect Immun* 69: 602-606.
 65. Colamussi ML, White MR, Crouch E, Hartshorn KL (1999) Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. *Blood* 93: 2395-2403.
 66. Bakaletz LO (1995) Viral potentiation of bacterial superinfection of the respiratory tract. *Trends Microbiol* 3: 110-114.
 67. Allen EK, Koeppl AF, Hendley JO, Turner SD, Winther B, et al. (2014) Characterization of the nasopharyngeal micro biota in health and during rhinovirus challenge. *Microbiome* 2: 22.
 68. Stearns JC, Davidson CJ, McKeon S, Whelan FJ, Fontes ME, et al. (2015) Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age. *ISME J* 9: 1246-1259.
 69. Adlerberth I, Wold AE (2009) Establishment of the gut micro biota in Western infants. See comment in PubMed Commons below *Acta Paediatr* 98: 229-238.
 70. Biesbroek G, Tsvitsivadze E, Sanders EA, Montijn R, Veenhoven RH, et al. (2014) Early respiratory micro biota composition determines bacterial succession patterns and respiratory health in children. *Am J Respir Crit Care Med* 190: 1283-1292.
 71. Teo SM, Mok D, Pham K, Kusel M, Serralha M, et al. (2015) Inouye, M. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 17: 704-715.
 72. Berrington JE, Cummings SP, Embleton ND (2014) The nasopharyngeal micro biota: an important window of opportunity. *Am J Respir Crit Care Med* 190: 246-248.
 73. Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV (2015) Probiotics and immunity: provisional role for personalized diets and disease prevention. *EPMA J* 6: 14.
 74. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, et al. (2016) The gut micro biota and host health: a new clinical frontier. *Gut* 65: 330-339.
 75. Berggren A, Lazou Ahren I, Larsson N, Onning G (2011) Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. *Eur J Nutr* 50: 203-210.
 76. Cáceres P, Montes S, Vega N, Cruchet S, Brunser O, et al. (2010) Effects of HN001 on acute respiratory infections and intestinal secretory IgA in children. *S* 353-362.
 77. Fujita R, Iimuro S, Shinozaki T, Sakamaki K, Uemura Y, et al. (2013) Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: a multicenter, double-

- blinded, randomized comparative study in users of day care facilities for the elderly population. *Am J Infect Control* 41: 1231-1235.
78. Makino S, Ikegami S, Kume A, Horiuchi H, Sasaki H, et al. (2010) Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with *Lactobacillus delbrueckii* ssp. *bulgaricus* OLL1073R-1. *Br J Nutr* 104: 998-1006.
79. Merenstein D, Murphy M, Fokar A, Hernandez RK, Park H, et al. (2010) Use of a fermented dairy probiotic drink containing *Lactobacillus casei* (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. *Eur J Clin Nutr* 64: 669-677.
80. Rerksupphaphol S, Rerksupphaphol L (2012) Randomized controlled trial of probiotics to reduce common cold in schoolchildren. *Pediatr Int* 54: 682-687.
81. Río ME, Zago Beatriz L, Garcia H, Winter L (2002) The nutritional status change the effectiveness of a dietary supplement of lactic bacteria on the emerging of respiratory tract diseases in children. *Arch Latinoam Nutr* 52: 29-34.
82. Cobo Sanz JM, Mateos JA, Muñoz Conejo A (2006) Effect of *Lactobacillus casei* on the incidence of infectious conditions in children. *Nutr Hosp* 21: 547-551.
83. Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R (2013) Effect of *Lactobacillus rhamnosus* LGG(R) and *Bifidobacterium animalis* ssp. *lactis* BB-12(R) on health-related quality of life in college students affected by upper respiratory infections. *Br J Nutr* 109: 1999-2007.
84. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, et al. (2005) Effect of *Lactobacillus gasseri* PA 16/8, *Bifidobacterium longum* SP 07/3, *B. bifidum* MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. *Clin Nutr* 24: 481-491.